Integrating Pain-CBT Into an mHealth Analgesic Support Intervention for Patients With Chronic Pain From Advanced Cancers
NCT06722014
Advanced Cancer, Mental Disorders
Boston, Massachusetts, United States
View Trial DetailsNCT Number: NCT03814993
Multicenter observational study to determine the long-term tolerability and analgesic effectiveness of oral tapentadol in patients suffering from severe pain syndromes, refractory to other strong opioids.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
AZ Monic, Antwerp, Belgium
Tapentadol, a centrally acting analgesic. It is indicated in Europe "for the relief of moderate to severe acute pain in adults, which can be adequately managed only with opioid analgesics" (IR formulation/oral solution) and "for the management of severe chronic pain in adults, which can be adequately managed only with opioid analgesics" (SR formulation). Tapentadol is reimbursed in Belgium since May 1, 2018. The reimbursement was obtained through an article 81 procedure (Chapter IV) which means that the reimbursement is currently restricted to the time frame of the contract and that during that period certain questions and uncertainties regarding the use of tapentadol in a Belgian setting need to be answered. In order to answer the questions raised by the Belgian Healthcare authorities, this study will be performed evaluating the application of oral tapentadol in routine clinical practice in Belgium. The study is conceived as a nation-wide multicentre prospective non-interventional trial. The primary endpoint and secondary endpoints of this study are guided by the questions that need to be answered during the course of the contract reimbursement, as established by the Belgian health authorities.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: baseline - week 15
Differences in occurence of the PRO-CTCAE items: Nausea, vomiting and constipation
Time frame: baseline - week 52
Difference in frequency, severity and interference of selected PRO-CTCAE items
Time frame: baseline - week 52
Reduction in pain intensity numeric rating scale (PI-NRS). Scale: 0 = no pain and 10 = worst possible pain
Time frame: baseline - week 52
Change of healt-related quality of life measured by EQ-5D-5L (monthly evaluation)
Time frame: baseline - week 52
Change of healt-related quality of life measured SF-36 (monthly evaluation)
Time frame: baseline - week 52
Change of functional status measured by GPE-DV (monthly evaluation)
Time frame: baseline - week 52
Change of functional status measured by impact pain on functioning (Interference-BPI)
Time frame: baseline - week 52
Change of functional status measured by SF-36 (monthly evaluation)
Time frame: baseline - week 52
Occurence of tolerance by the use of MQS-III questionnaire (weekly or monthly)
Time frame: baseline - week 52
Occurence of tolerance by the use time-point of discontinuation of study drug
Time frame: baseline - week 52
By the use of MQS-III questionnaire
Dafne Balemans
Other
Multicenter Observational Study to Determine the Long-term Tolerability and Analgesic Effectiveness of Oral Tapentadol in Patients Suffering From Severe Pain Syndromes, Refractory to Other Strong Opioids.
Acronym: PLATINUM
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06722014
Advanced Cancer, Mental Disorders
Boston, Massachusetts, United States
View Trial DetailsNCT07680231
Lumbar Pain Syndrome, Mental Disorders
Giza, Egypt
View Trial DetailsNCT00106223
Body Dysmorphic Disorder, Body Dysmorphic Disorders
Charlestown, Massachusetts, United States
View Trial DetailsNCT05834725
Chronic Pain, Mental Disorders
Philadelphia, Pennsylvania, United States
View Trial Details